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Background. Single low-dose primaquine (PQ) reduces Plasmodium falciparum infectivity before it impacts gametocyte den-
sity. Here, we examined the effect of PQ on gametocyte sex ratio as a possible explanation for this early sterilizing effect.
Methods. Quantitative reverse-transcription polymerase chain reaction assays were developed to quantify female gametocytes 
(targeting Pfs25 messenger RNA [mRNA]) and male gametocytes (targeting Pf3D7_1469900 mRNA) in 2 randomized trials in 
Kenya and Mali, comparing dihydroartemisinin-piperaquine (DP) alone to DP with PQ. Gametocyte sex ratio was examined in 
relation to time since treatment and infectivity to mosquitoes.
Results. In Kenya, the median proportion of male gametocytes was 0.33 at baseline. Seven days after treatment, gametocyte 
density was significantly reduced in the DP-PQ arm relative to the DP arm (females: 0.05% [interquartile range {IQR}, 0.0–0.7%] 
of baseline; males: 3.4% [IQR, 0.4%–32.9%] of baseline; P < .001). Twenty-four hours after treatment, gametocyte sex ratio became 
male-biased and was not significantly different between the DP and DP-PQ groups. In Mali, there was no significant difference in 
sex ratio between the DP and DP-PQ groups (>0.125 mg/kg) 48 hours after treatment, and gametocyte sex ratio was not associated 
with mosquito infection rates.
Conclusions. The early sterilizing effects of PQ may not be explained by the preferential clearance of male gametocytes and may 
be due to an effect on gametocyte fitness.
Keywords. sex ratio; primaquine; artemisinin; dihydroartemisinin; piperaquine.
 
Artemisinin combination therapies (ACTs) have contributed 
substantially to declines in the burden of falciparum malaria 
in the last 15  years [1], due to their rapid clearance of asex-
ual stage parasites and activity against immature gametocytes 
[2, 3]. ACTs reduce the posttreatment transmission potential 
of parasites from infected humans to mosquitoes more than 
nonartemisinin treatments [4, 5]. However, because of their 
incomplete activity against mature gametocytes, patients may 
remain infective to mosquitoes for up to 2 weeks after ACT 
treatment [6–8]. The only currently available drug able to clear 
mature sexual stage malaria parasites is the 8-aminoquino-
line primaquine (PQ) [9], which has been used historically 
for gametocyte clearance as a single dose of 0.75  mg base/kg 
PQ in combination with a schizonticide [5, 8–12]. Concerns 
about hemolysis in individuals with glucose 6-dehydrogenase 
(G6PD) deficiency have contributed to the recent revision of 
the recommended dose for Plasmodium falciparum gametocyte 
clearance to 0.25 mg base/kg. The World Health Organization 
recommends that this low dose be provided alongside standard 
ACT without prior G6PD status screening, for the prevention 
of P. falciparum transmission in areas with ACT-resistant para-
sites, or areas close to elimination [13].
Though the aim of PQ treatment for P. falciparum is a reduc-
tion in gametocyte infectivity, there is limited direct evidence on 
mosquito infection prevalence in individuals treated with the 
currently recommended low dose [9, 14, 15]. In a recent trial 
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where PQ was combined with a current ACT, the number of indi-
viduals infecting mosquitoes dropped from 93.3% to 6.7% over a 
time window when gametocyte prevalence and density appeared 
unaffected by PQ [14]. This pattern appears consistent; a review 
of P.  falciparum transmission after PQ treatment shows that 
gametocyte infectivity is generally diminished prior to observ-
able changes in gametocyte abundance [9]. An as yet untested 
hypothesis is that PQ may disproportionally affect male gameto-
cytes and thus sterilize infections while gametocyte densities, 
largely determined by the more abundant female gametocytes 
[16–19], remain stable [20]. In vitro studies with Plasmodium 
berghei show that male gametocytes are more sensitive to a range 
of antimalarials [21], but PQ requires bioactivation in the liver, so 
in vitro studies are not possible. Because posttreatment gameto-
cyte densities are commonly below the microscopic threshold for 
detection, molecular sex-specific gametocyte assays are required 
to test this hypothesis in clinical trials. The only previously pub-
lished male gametocyte marker is insufficiently sensitive to quan-
tify low-density male gametocytes [19].
Here, we present results from 2 randomized controlled tri-
als of PQ in combination with dihydroartemisinin-piperaquine 
(DP), conducted in Kenya and Mali. While this is the first 
report on the trial in Kenya, gametocyte dynamics and trans-
mission data (but not gametocyte sex ratio) were previously 
presented for the trial in Mali [14]. In this report, we assess the 
effect of PQ on gametocyte sex ratio using quantitative reverse- 
transcription polymerase chain reaction (qRT-PCR) with sex- 
specific RNA markers [19], including a highly sensitive novel 
male marker selected using sex-specific P. falciparum transcrip-
tomic data (Pf3D7_1469900) [22]. Our analysis allowed the first 
direct assessment of the effect of PQ on gametocyte sex ratio 
and subsequent infectivity to mosquitoes.
METHODS
Study Design and Participants
The Kenyan trial was conducted in Mbita point, western Kenya, 
between September 2014 and September 2015. The study area is 
characterized by moderate malaria transmission [23]. During vis-
its to local schools, 5- to 15-year-olds providing written consent 
for screening were tested for malaria infection by examination of 
100 fields of a thick blood smear. Participants providing written 
informed consent were eligible if they were patent gametocyte 
carriers (1 gametocyte per 500 white blood cells [WBCs] in a 
thick film), 5–15 years of age, with P. falciparum monoinfection. 
Exclusion criteria were hemoglobin density of <9.5 g/dL, asex-
ual parasite density of >200 000 parasites/µL, body mass index 
of <16  kg/m2 or >32  kg/m2, tympanic temperature of >39°C, 
antimalarial treatment taken within 2  days, recent treatment 
with drugs known to be metabolized by the cytochrome P450 
(CYP) 2D enzyme family, history of adverse reaction to study 
drugs, blood transfusion within 90 days, history or symptoms 
of chronic illness, or family history of any condition associated 
with extended QTc interval. The trial protocol received ethi-
cal approval from the Kenya Medical Research Institute Ethics 
Review Committee (#439), and the London School of Hygiene 
and Tropical Medicine Observational/Interventional Research 
Ethics Committee (#7323).
Procedures
All participants received a 3-day course of DP (Eurartesim, 
Sigma-Tau, Italy) alone or with a single low dose of PQ (0.25 mg 
base/kg) on the third day of DP treatment (day 2 of the trial). 
Enrollees and trial staff other than the trial pharmacist, who was 
involved only in randomization and drug administration, were 
blinded to treatment arm allocation.
Primaquine (Sanofi-Aventis US LLC, Bridgewater, New 
Jersey) was prepared as previously described by dissolving 
crushed 1-mg tablets into distilled water and mixing with a 
taste-masking solution to a final concentration of 0.25 mg/kg 
child weight [8, 24]. Participants assigned to the placebo arm 
received the same total volume of water and masking solution.
Participants were examined at the study clinic on days 0, 1, 
2, 3, 7, and 14 after enrollment. Blood samples were taken at all 
time points except for day 1, either by fingerpick (day 0, day 2, 
and day 14) or venipuncture (day 3 and day 7). At all sampling 
points, hemoglobin levels were quantified by Hemocue pho-
tometer (HemoCue AB, Sweden), and asexual parasites and 
gametocytes were enumerated by examination of a Giemsa-
stained thick film counting against 200 or 500 WBCs, respec-
tively, and converted to densities per microliter assuming 
8000 WBCs/µL. Two assays were used for gametocyte detec-
tion: quantitative nucleic acid–based sequence amplification 
(QT-NASBA) was used to determine gametocyte prevalence 
at enrollment and days 2, 3, 7, and 14 following treatment; 
qRT-PCR was used for gametocyte quantification [25] and 
sex ratio.
To validate our sex-specific qRT-PCR assays, we first con-
firmed the ability to generate populations of male and female 
gametocytes using a recently published PfDynGFP/P47mCherry 
reporter line (Supplementary Figures 1–3). Then, we developed 
and optimized sex-specific qRT-PCR assays amplifying mes-
senger RNA (mRNA) specific to the Pfs25 (female marker) 
and Pfs230p (male marker) genes [19] and more sensitive male 
targets (Supplementary Table 1). Pfs230p also showed limited 
sensitivity in our preliminary analyses (Supplementary Tables 
2 and 3), and in our baseline surveys (gametocytes were unde-
tectable in 9/112 of baseline samples using Pfs230p). We thus 
designed a new qRT-PCR based on a more abundant gene tran-
script specific to male gametocytes; Pf3D7_1469900 (hereafter, 
PfMGET for male gametocyte–enriched transcript) [22]. In 
the Supplementary Data, we provide details of target selection 
(Supplementary Table  2), the development and validation of 
the PfMGET qRT-PCR assay (Supplementary Tables 3–6), and 
details on molecular gametocyte assay methodology for the 
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Kenya and Mali trials. Pfs25 and PfMGET assays showed similar 
sensitivity, and a threshold for positivity was set at 1 gametocyte 
per sample (0.002/µL) for both assays.
At day 3 and day 7, blood was provided to mosquitoes for 
direct membrane feeding assays, as previously described [26]. 
Low infectivity (38 oocyst-positive mosquitoes out of 8686 dis-
sected, from 2 individuals in the DP arm) prompted additional 
feeds (n = 32) to be conducted with serum replacement at days 
0, 3, and 7. Mosquitoes remained uninfected in these conditions. 
Later it was discovered that the Anopheles gambiae sensu stricto 
colony was infected with Microsporidia species, which have been 
shown to inhibit Plasmodium survival in mosquitoes [27] and 
precluded meaningful assessments of infectivity in this trial.
To test our findings in an independent dataset, and explore 
the relationship between sex ratio and infectivity, we performed 
a subsidiary analysis of blood samples from participants of a 
single blind, dose-ranging, randomized trial of DP with PQ 
conducted near Ouelessebougou, Mali [14]. Primaquine 
was provided with the first dose of DP at baseline, at doses 
of 0.0625  mg/kg (n  =  16), 0.125  mg/kg (n  =  16), 0.25  mg/kg 
(n = 15), and 0.5 mg/kg (n = 17) (control with DP only, n = 16). 
The main outcomes of this trial were previously reported [14]. 
For the current study, blood samples were available from base-
line and from 2, 3, 7, and 14 days after the administration of PQ. 
Direct membrane feeding assays for the assessment of infectiv-
ity to A.  gambiae mosquitoes were successfully performed at 
baseline and at days 2 and 7 [14, 26].
Sample Size Calculations
Sample size calculations were based on the anticipated pri-
mary outcome, the prevalence of infectivity to mosquitoes in 
membrane feeding assays. A previous study in the same setting 
showed that 30% of submicroscopic gametocyte carriers and 
80% of patent gametocyte carriers infected mosquitoes 7 days 
after DP treatment [7]. Assuming a conservative estimate of 
30% infection after DP and assuming PQ would reduce this to 
<5% [28], a sample size of 60 participants per treatment arm, 
allowing for 10% loss to follow-up, was considered sufficient to 
detect this difference in infection rate with 90% power at a sig-
nificance level of .05.
5525 patients were assessed for eligibility
161 patients had P. falciparum
gametocytes
120 P. falciparum gametocyte carriers
were enrolled, and randomly assigned to
receive either DP + Placebo, or DP + PQ
60 receive DP + Placebo
37   , 23  
30 5–10 yrs, 30 10–15 yrs
57 DP + Placebo
completed the trial
35   , 22  
29 5–10 yrs, 28 10–15 yrs
3 patients were removed from
the study
1 required treatment for a
concurrent infection
3 withdrew consent on d7 58 received DP + PQ
completed the trial
31   , 27  
28 5–10 yrs, 30 10–15 yrs
2 patients were removed from
the study
1 began a self-prescribed
course of  artemther-
lumefantrine on d4
1 withdrew consent on d7
60 receive DP + PQ
33   , 27  
29 5–10 yrs, 31 10–15 yrs
5405 patients were not eligible for
enrollment screening:
41 Gametocyte carriers were not eligible
for enrollment:
10 had P. malariae cross-infection
4 had P. ovale cross-infection
1 had P. malariae and P. ovale cross-
infection
3 had <9.5g/dL Hb
23 did not consent for full trial
participation
3861 had no observable Plasmodium
infection by microscopy
1503 patients with Plasmodium
infection had no observable
gametocytes
Figure 1. Screening and enrollment criteria. Abbreviations: ♀, female; ♂, male; DP, dihydroartemisinin-piperaquine; Hb, hemoglobin; PQ, primaquine (0.25 mg/kg).
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Data Analysis
The primary efficacy endpoint for the Kenyan trial was the 
mean gametocyte clearance time (ie, number of days until 
gametocytes become undetectable by QT-NASBA [24] in the 
DP-PQ arm compared to the DP arm), calculated using pre-
viously presented mathematical models that allow clearance 
time to be extrapolated beyond the period of follow-up [29]. 
Secondary endpoints were the area under the curve (AUC) 
of QT-NASBA–based gametocyte density over time (gameto-
cytes/µL-1 days) [5] using log10 gametocyte density in linear 
regression models with adjustment for baseline gametocyte 
density, and qRT-PCR gametocyte prevalence, density, and sex 
ratio (proportion of total gametocytes that were male) at days 3 
and 7. Stata software version 12.0 (StataCorp, College Station, 
Texas) and SAS software version 9.3 (SAS Institute, Cary, North 
Carolina) were used for statistical analysis. Baseline measures 
were compared between treatment arms using Student t test, 
Wilcoxon rank-sum tests, or χ2 tests. Differences between 
treatment arms in gametocyte prevalence and (log10-trans-
formed) density after baseline were assessed with linear and 
logistic models, after adjusting for gametocyte density at 
baseline. Differences in the proportion of male gametocytes 
between treatment arms were compared with Wilcoxon rank-
sum tests at baseline, and linear models adjusted for baseline 
gametocyte density after treatment. Proportions within treat-
ment arms were compared to paired baseline measures with 
Wilcoxon signed-rank test. The accuracy of gametocyte sex 
ratio estimates depends on the total number of gametocytes 
detected. To ensure robust sex ratio estimates, ratio analy-
ses were restricted to samples with total qRT-PCR estimated 
counts of >16 gametocytes per sample [30], resulting in mini-
mum gametocyte per microliter thresholds of 0.032 for Kenyan 
samples and 0.32 for Malian samples.
RESULTS
A total of 5525 children were screened, and 120 gametocyte car-
riers were enrolled into the Kenyan trial (Figure 1). Sixty were 
assigned to receive DP with a placebo, and 60 were assigned to 
receive DP-PQ. Four participants in the DP arm and 2 in the 
DP-PQ arm were lost to follow-up or excluded from the trial. 
The lowest hemoglobin concentration recorded during the trial 
was 6.9  g/dL, observed in 1 individual prior to PQ adminis-
tration who was excluded from the trial. Minimum recorded 
hemoglobin level in all other participants was 8.6 g/dL.
Gametocyte density at baseline was not significantly different 
between treatment arms by microscopy (P = .705) or qRT-PCR 
(females: P = .692; males: P = .784; combined males and females: 
P = .823) (Table 1). The median proportion of male gametocytes 
at baseline was 0.33 (IQR, 0.22–0.49) in the DP arm, and 0.32 
(IQR, 0.17–0.53) in the DP-PQ arm (P  =  .547); that is, a sex 
ratio of approximately 1 male to 2 females (Table 2).
Gametocytocidal Efficacy of Low-Dose PQ
QT-NASBA gametocyte prevalence on day 3 (24 hours after 
PQ) was 89.3% (50/56) in the DP arm and 96.6% (56/58) in the 
DP-PQ arm (P < .093) (Figure 2; Table 2). At day 7, gametocyte 
prevalence by QT-NASBA was 85.7% (48/56) in the DP arm 
and 37.9% (22/58) in the DP-PQ arm (P < .001). The estimated 
mean time to gametocyte clearance in our selective population 
with high starting gametocyte densities was 49.2 (95% con-
fidence interval [CI], 30.6–67.9) days in the DP arm and 9.8 
(95% CI, 7.7–12.0) days in the DP-PQ arm (P < .001). For DP, 
this estimate was based on an extrapolation of QT-NASBA data 
beyond the duration of follow-up and should therefore be inter-
preted with caution.
All gametocyte density and sex ratio estimates were based 
on qRT-PCR. As a consequence of the higher input material 
for qRT-PCR in the Kenya trial (500  µL of whole blood for 
extraction, eluted in 10.5 µL water) compared to QT-NASBA 
(50  µL of whole blood for extraction eluted in 50  µL water), 
Table 1. Characteristics of the Study Population at Baseline
Characteristic/Measure
DP + Placebo 
(n = 56)
DP + 0.25 mg/kg 
PQ (n = 58) P Value
Demographics and health
 Female, % (no./No.) 39.3 (22/56) 46.55 (27/58) .433
 Age, y, median (IQR) 9.5 (7–11) 10 (7–12) .948
 Hemoglobin, g/dL, median 
(IQR)
11.9 (10.7–13.0) 12.0 (11–12.4) .753
Microscopy
 Asexual prevalence, % 
(no./No.)
69.09 (38/55) 59.7 (34/57) .297
 Asexual density, para-
sites/μL, median (IQR)
360 (0–1600) 120 (0–800) .133
 Gametocyte prevalence, 
% (no./No.)
100.0 (55/55) 100.0 (56/56) NC
 Gametocyte density, para-
sites/μL, median (IQR)
32 (16–64) 32 (16–48) .705
qRT-PCR
 Total gametocyte preva-
lence, % (no./No.)
100.0 (54/54) 100.0 (57/57) NC 
 Total gametocyte density, 
parasites/μL, median 
(IQR)
10.84 (3.06–69.97) 11.87 (4.16–55.80) .823
 Male gametocyte preva-
lence, % (no./No.)
100.0 (54/54) 100.0 (57/57) NC 
 Male gametocyte density, 
parasites/μL, median 
(IQR)
3.76 (0.78–11.16) 3.09 (0.811–14.14) .784
 Female gametocyte prev-
alence, % (no./No.)
100.0 (55/55) 100.0 (57/57) NC 
 Female gametocyte 
density, parasites/μL, 
median (IQR)
6.66 (0.85–36.60) 7.64 (1.59–23.92) .692
Data are shown as median (IQR) or % (positive/total sample size). Densities are presented 
for all individuals.
Abbreviations: DP, dihydroartemisinin-piperaquine; IQR, interquartile range; NC, not cal-
culable; PQ, primaquine; qRT-PCR, quantitative reverse-transcription polymerase chain 
reaction.
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qRT-PCR gametocyte prevalence was considerably higher. 
At day 3, total gametocyte density determined by qRT-PCR 
was decreased to 24.81% (IQR, 9.54%–48.29%) of its level at 
baseline in the DP arm, and 35.73% (IQR, 14.39%–80.82%) 
in the DP-PQ arm (P value after adjustment for baseline den-
sity =  .03). By day 7, total gametocyte density was decreased 
to 22.31% (IQR, 7.38%–78.22%) of its baseline level in the 
DP arm, and 1.43% (IQR, 0.22%–8.19%) in the DP-PQ arm 
(P  <  .001). Gametocyte AUC was significantly lower in the 
DP-PQ arm (P = .018).
Effect of DP and PQ on Male and Female Gametocytes
By day 3, female gametocyte density was decreased to a median 
of 9.1% (IQR, 1.3%–33.5%) of its baseline level in the DP arm, 
and 14.0% (IQR, 2.9%–65.2%) of its baseline level in the DP-PQ 
arm (P = .152) (Table 2; Figure 3). Male density decreased less 
substantially over the same period (DP:  40.1% [IQR, 15.8%–
86.6%] of baseline; DP-PQ:  61.8% [IQR, 27.7%–191.6%] of 
baseline; P = .035), resulting in male-biased sex ratios in both 
treatment arms (DP: 0.70 [IQR, 0.47–0.91]; DP-PQ: 0.68 [IQR, 
0.35–0.93]; P = .625).
At day 7, the density of gametocytes was significantly reduced 
in the DP-PQ arm relative to the DP arm (females: 0.05% [IQR, 
0.0–0.7%] of baseline; males: 3.4% [IQR, 0.4%–32.9%] of base-
line; P < .001). In the DP arm, sex ratios were lower than at day 
3 but still higher than baseline (median proportion male: 0.44 
[IQR, 0.26–0.68]; P  =  .002). Sex ratios among the low densi-
ties of gametocytes in the DP-PQ arm were significantly more 
male biased than in the DP arm (median proportion male: 0.98 
[IQR, 0.89–1.00]; P  <  .001 for matched measures at baseline, 
and group comparison with DP arm).
Effect of DP and PQ on Gametocyte Sex Ratio in Relation to Infectivity to 
Mosquitoes in an Independent Trial in Mali
Pfs25 qRT-PCR–based gametocyte prevalence, density, and 
infectivity to mosquitoes for the trial in Mali have been 
reported elsewhere [14]. At baseline the median proportion of 
male gametocytes was 0.15 (IQR, 0.09–0.27) overall, and did 
not differ between any DP-PQ arms and the DP arm (P = .414–
.996) (Figure 4). At day 2 (48 hours after PQ administration), 
there was a significant decrease in the proportion of individuals 
infecting mosquitoes and the proportion of mosquitoes these 
individuals infected at all PQ doses of >0.125 mg/kg (Figure 4). 
The median proportion of gametocytes that were male at day 
2 was 0.28 (IQR, 0.14–0.53) in the DP arm. Adjusted for base-
line gametocyte density, the proportion of male gametocytes 
was borderline significantly different in the 0.0625 mg/kg PQ 
arm (0.14 [IQR, 0.09–0.27]; P  =  .052), but not in any high-
er-dose PQ arms (proportion male: 0.15–0.55; P = .085–.434). 
The proportion of male gametocytes was similar between DP 
and DP-PQ arms at day 3 (P ≥  .358), but became highly male 
Table 2. Gametocyte Measures in the Kenyan Study
Measure DP + Placebo (n = 56) DP + PQ (n = 58) P Value
Microscopy and QT-NASBA
 Gametocyte prevalence, % (no./No.) (microscopy)
  Day 0 100.0 (55/55) 100.0 (56/56) NC
  Day 2 44.4 (24/54) 40.0 (22/55) .803
  Day 3 44.4 (24/54) 42.9 (24/56) .811
  Day 7 29.6 (16/54) 7.1 (4/56) .006
  Day 14 9.6 (5/52) 0 (0/56) NC 
 Gametocyte prevalence, % (no./No.) (QT-NASBA)
  Day 0 98.2 (55/56) 98.3 (57/58) .980
  Day 2 94.6 (53/56) 98.3 (56/57) .334
  Day 3 89.3 (50/56) 96.6 (56/58) .093
  Day 7 85.7 (48/56) 37.9 (22/58) <.001
  Day 14 81.8 (45/55) 8.62 (5/58) <.001
 Gametocyte 
clearance time, 
d (95% CI)
49.2 (30.6–67.8) 9.8 (7.7–12.0) <.001
 Gametocyte AUC/ 
gams/µL-1 d, 
median (IQR)
55.4 (26.9–154.5) 35.4 (12.8–70.1) .018
Sex-specific qRT-PCR
 Female gametocyte prevalence, % (no./No.) (Pfs25)
  Day 0 100.0 (55/55) 100.0 (57/57) NC 
  Day 3 92.7 (50/55) 94.7 (51/57) .816
  Day 7 88.9 (48/54) 71.4 (33/56) .001
 Male gametocyte prevalence, % (no./No.) (PfMGET)
  Day 0 100.0 (54/54) 100.0 (57/57) NC 
  Day 3 96.4 (54/56) 96.5 (55/57) .931
  Day 7 96.3 (52/54) 96.5 (53/57) .465
 Total gametocyte prevalence, % (no./No.) (Pfs25 and PfMGET)
  Day 0 100.0 (54/54) 100.0 (57/57) NC 
  Day 3 96.4 (53/55) 96.5 (55/57) .920
  Day 7 96.3 (52/54) 96.4 (52/56) .933
 Female gametocyte density, gams/µL (Pfs25)
  Day 0 6.650 (0.851–36.599) 7.640 (1.594–23.916) .692
  Day 3 0.427 (0.054–2.403) 1.307 (0.111–6.277) .152
  Day 7 0.831 (0.080–3.122) 0.003 (0.000–0.055) <.001
 Male gametocyte density, gams/µL (PfMGET)
  Day 0 3.762 (0.778–11.164) 3.084 (0.8114–14.142) .784
  Day 3 1.511 (0.303–8.854) 1.920 (0.476–12.387) .035
  Day 7 0.870 (0.213–4.749) 0.137 (0.0140–0.600) <.001
 Total gametocyte density, gams/µL (Pfs25 and PfMGET)
  Day 0 10.836 (3.056–69.973) 11.870 (4.157–55.800) .823
  Day 3 2.864 (0.495–14.707) 4.167 (1.128–18.080) .030
  Day 7 2.509 (0.631–7.136) 0.140 (0.018–0.855) <.001
 Proportion male, median (IQR)
  Day 0 0.338 (0.222–0.493) 0.323 (0.171–0.525) .457
  Day 3 0.692 (0.475–0.910) 0.677 (0.345–0.928) .634
  Day 7 0.457 (0.278–0.732) 0.979 (0.868–1.000) <.001
 Proportion male, median (IQR) (≥16 gams/sample only)
  Day 0 0.332 (0.222–0.492) 0.323 (0.171–0.525) .457
  Day 3 0.700 (0.472–0.911) 0.677 (0.345–0.928) .635
  Day 7 0.441 (0.262–0.683) 0.977 (0.891–0.996) <.001
Data are presented as median (IQR) or % (positive/total sample size). Densities are pre-
sented for all individuals.
Abbreviations: AUC, area under the curve; DP, dihydroartemisinin-piperaquine; gams, 
gametocytes; IQR, interquartile range; NC, not calculable; PQ, primaquine; qRT-PCR, quan-
titative reverse-transcription polymerase chain reaction; QT-NASBA, quantitative nucleic 
acid–based sequence amplification.
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biased compared to the DP arm in the 0.25  mg/kg and 0.5 
mg/kg DP-PQ arms by day 7 (DP: 0.29 [IQR, 0.24–0.41]; DP-PQ 
0.25 mg/kg: 0.80 [IQR, 0.13–0.89], P = .035; DP-PQ 0.5 mg/kg: 
1.0 [IQR, 0.99–1.0], P < .001). Increasing PQ doses reduced the 
female bias of gametocytes by day 7 (Supplementary Table 7). 
Within each treatment arm, the proportion of male gameto-
cytes at day 7 was significantly higher relative to baseline in 
the DP (P = .016) and the DP-PQ 0.125 mg/kg (P = .033) and 
0.5 mg/kg (P = .043) dose groups, but not in the 0.0625 mg/kg 
(P = .477) or 0.25 mg/kg (P = .080) dose groups. There was no 
significant difference in the proportion of male gametocytes 
between infectious and noninfectious individuals at baseline 
(infectious/noninfectious: 55/26; P = .964), at day 2 (infectious/
noninfectious: 21/57; P = .531), or at day 7 (infectious/nonin-
fectious: 5/71; P = .244) (Figure 5).
DISCUSSION
Our findings support the effectiveness of a single dose of PQ 
(0.25  mg/kg) for shortening gametocyte carriage following 
ACT treatment [13]. Our sex-specific qRT-PCR suggests that 
PQ may not preferentially clear male gametocytes. At early time 
points when PQ has been shown to substantially decrease infec-
tiousness to mosquitoes (24–48 hours) [14, 20], the proportion 
of gametocytes that were male was comparable between the 
DP-PQ and DP-only arms.
Before treatment, there is a nonlinear relationship between 
gametocyte density and infectivity to mosquitoes [31–33]. After 
PQ treatment, gametocyte density has no obvious relationship 
with infectivity, and infections appear to be sterilized [14, 20, 
24]. White and colleagues highlighted these phenomena in 
historic studies and urged that trials of PQ efficacy based on 
gametocyte density measures be interpreted with caution [20]. 
In a recent PQ efficacy trial, it was postulated that because 
gametocytes were quantified using Pfs25-based molecular 
assays, only female gametocytes were counted, while infections 
may have been sterilized by clearance of the smaller undetected 
male population [14]. If total clearance of one sex was the cause 
of PQ’s rapid sterilizing effects, a highly sensitive sex-specific 
assay would be capable of predicting posttreatment infectivity. 
Though we believe the assay presented in the current man-
uscript meets these requirements, our data indicate that PQ 
treatment has a similar effect to ACT treatment in terms of 
absolute sex ratio, in the days after treatment where infections 
are sterilized. The extent of the effect varied between the 2 trials 
we describe in the current study and may relate to the timing of 
PQ and ACT administration and to the limited sample size of 
treatment arms in the Malian trial. However, neither trial pro-
vides evidence of the hypothesized increase in female bias after 
PQ treatment; the Kenyan trial indicates that male gametocytes 
may actually be cleared more slowly than females by both DP 
and DP-PQ. While gametocyte sex ratio is an important deter-
minant of transmissibility and may be associated with gameto-
cyte density, we observed no relation between posttreatment 
gametocyte sex ratio and infectivity. Collection of RNA samples 
from a larger number of gametocyte donors participating in 
mosquito feeding studies conducted prior to drug administra-
tion would allow more rigorous assessment of gametocyte sex 
ratio and its effect on the likelihood of onward transmission in 
natural infections.
Our findings do not exclude the possibility that PQ’s sterilizing 
effects are sex specific. The P. berghei–based in vitro dual gamete 
formation assay has shown that male gametocytes are more sus-
ceptible to a range of drugs with different modes of action [21]. 
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temisinin-piperaquine (DP)–only arm at day 0 (576, 608, and 686/µL), and 1 in the 
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The advantage of this system is that its endpoint (exflagellation in 
males, production of the translationally repressed Pfs25 protein 
in activated females) is based on gametocytes’ ability to activate 
(ie, their fitness) rather than the presence of their mRNA, which 
may remain detectable in nonfunctional intact gametocytes. 
Quantifying gametocytes based on mRNA transcript numbers 
has limitations [34]. We used automated RNA extraction to 
minimize variation in extraction efficiency and assessed mRNA 
transcript numbers during gametocyte maturation. mRNA tran-
scripts of Pfs25 and PfMGET increased sharply from stage II 
to stage V gametocytes after which we found no evidence for 
age-dependent transcription patterns that may explain our find-
ings of a faster reduction of female-specific transcripts follow-
ing treatment (Supplementary Figure 4). Our findings suggest 
that the early sterilizing effect of PQ may be a consequence of 
a reduced fitness, rather than immediate clearance of 1 or both 
gametocyte sexes. Delves et  al showed that percentage inhibi-
tion of activation by dihydroartemisinin was approximately 14 
times higher for male gametocytes than females [21]. Though 
this appears to conflict with our observation that male gameto-
cytes are cleared more slowly by DP-PQ, both observations may 
be valid if (male) gametocytes were rendered nonfunctional by 
DP-PQ but remained in the circulation during sampling. As 
such, our study supports the notion that functional assays (be it 
gametocyte fitness or infectivity) are essential to determine the 
transmission-blocking properties of antimalarial drugs.
Observations of microscopy’s insensitivity [6, 35–38] and the 
significance of submicroscopic gametocyte densities for trans-
mission [39–41] have placed great import on quantifying the 
submicroscopic gametocyte reservoir. The recent realization that 
Pfs25 is transcribed specifically, or in far greater abundance in 
female gametocytes, affects previous interpretations of the Pfs25 
readout as measure of gametocyte density [19], as the male com-
ponent of gametocyte biomass will have gone largely undetected 
and thus total gametocyte density will have been underestimated.
The results of the current study shed some light on PQ’s 
early sterilizing activity. Determining gametocyte sex ratio 
may have significant utility for examining the relationship 
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Figure 3. Quantitative reverse-transcription polymerase chain reaction (qRT-PCR)–based male and female gametocyte density and proportion male in the Kenyan study. A, 
Proportion of total gametocyte density that is male (males per µL / [males per µL plus females per µL]), presented as individual data points, with the median and interquartile 
range (IQR). Proportion male was only presented or included in analyses if total gametocyte density was estimated to be ≥16 gametocytes per sample (1 gametocyte/500 
µL = 0.032 gametocytes/µL). B, Gametocyte density determined by qRT-PCR at baseline (day 0), and 24 (day 3) or 120 (day 7) hours after dihydroartemisinin-piperaquine (DP) 
or DP plus primaquine (PQ). Female gametocytes were quantified by extrapolating Pfs25 messenger RNA abundance from standard curves of known quantities of female 
gametocytes, and vice versa. Density is presented as median, IQR, and 10th–90th percentiles of gametocytes/µL for gametocyte-positive individuals only.
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between gametocyte density, sex, and infectivity to mosqui-
toes, and for the assessment of drugs causing clearance of one 
sex. However, our findings demonstrate that the preferential 
clearance of one gametocyte sex does not provide an expla-
nation for the rapid sterilizing effect of PQ. Trials assessing 
transmission-blocking effects of drugs such as PQ should thus 
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Figure 4. Infectiousness to mosquitoes, quantitative reverse-transcription polymerase chain reaction (qRT-PCR)–based male and female gametocyte density, and propor-
tion male in the Malian study. A, Prevalence of infectiousness to mosquitoes among the study population in the direct membrane-feeding assay at days 0, 2, and 7. Asterisks 
(*) indicate significantly different infectiousness in logistic regressions relative to control. Mosquito infection was determined as the presence of any number of oocysts in 
the mosquito mid-gut 7 days after feeding. B, Proportion of total gametocyte density that is male (males per µL / [males per µL plus females per µL]), presented as individual 
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Density is presented as median, IQR, and 10th–90th percentiles of gametocytes/µL for gametocyte-positive individuals only. Median female gametocyte density was calcu-
lated from <5 individuals in some dose arms at day 7 (0.5 mg/kg, n = 4) and day 14 (0.5 mg/kg, n = 2). Median male gametocyte density was calculated from <5 individuals in 
some dose arms at day 14 (0.25 mg/kg, n = 3; 0.5 mg/kg, n = 4).
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continue to rely on functional transmission read-outs such as 
mosquito feeding assays.
Supplementary Data
Supplementary materials are available at The Journal of 
Infectious Diseases online. Consisting of data provided by the 
authors to benefit the reader, the posted materials are not copy-
edited and are the sole responsibility of the authors, so questions 
or comments should be addressed to the corresponding author.
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